EUVIMEDEUVIMED entdecken
BeobachtungsstudieRandomisierte kontrollierte Studie

Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation

Julia Aulin iD, Karl Sjölin iD, Johan Lindbäck iD, Alexander P Benz, John W Eikelboom iD, Ziad Hijazi iD, Kim Kultima iD, Jonas Oldgren iD, Lars Wallentin iD, Joachim Burman iD, ACTIVE A and AVERROES Investigators

Circulation · 2024

DOI: 10.1161/circulationaha.124.069440 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Circulation, 2024. Verfasst von Julia Aulin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Cardiology (J.A., Z.H., J.O., L.W.)Uppsala University, Sweden. Hauptthemen laut MEDLINE: Atrial Fibrillation, Biomarkers, Stroke, Neurofilament Proteins. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Biomarkers reflecting brain injury are not routinely used in risk assessment of stroke in atrial fibrillation (AF). Neurofilament light chain (NFL) is a novel biomarker released into blood after cerebral insults. We investigated the association between plasma concentrations of NFL, other biomarkers, and risk of stroke and death in patients with AF not receiving oral anticoagulation. METHODS: For this observational study, baseline plasma samples were available from 3077 patients with AF randomized to aspirin in ACTIVE A (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events; 2003 to 2008) and AVERROES (Apixaban Versus Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment; 2007 to 2009). Median follow-up was 1.5 years. NFL was analyzed with a Single Molecule Array (Simoa). Associations with outcomes (total stroke or systemic embolism, ischemic stroke, cardiovascular death, and all-cause death) were explored with Cox regression models. RESULTS: In the combined cohort, the median NFL level was 16.9 ng/L (interquartile range, 11.1–26.5 ng/L), the median age was 71 years, 58% were men, and 13% had a history of previous stroke. NFL was associated with older age, higher creatinine, lower body mass index, previous stroke, female sex, and diabetes but not cardiac rhythm. Higher NFL was associated with a higher risk of stroke or systemic embolism (n=206) independently of clinical characteristics (hazard ratio, 1.27 [95% CI, 1.10–1.46] per doubling of NFL) and other biomarkers (hazard ratio, 1.18 [95% CI, 1.01–1.37]) and including in patients without previous stroke (hazard ratio, 1.23 [95% CI, 1.02–1.48]). NFL was also independently associated with cardiovascular (n=219) and all-cause (n=311) death. The C index for stroke using only NFL was 0.642, on par with the currently used clinical risk scores. Addition of information on NFL improved discrimination in a model also including clinical information, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and high-sensitivity cardiac troponin T, yielding a C index of 0.727. CONCLUSIONS: NFL reflects overt and covert episodes of cerebral ischemia and improves risk assessment of stroke and death in patients with AF without oral anticoagulation, including in patients without previous stroke. The combination of NFL with information on age, history of stroke, and other biomarkers should be explored as a future avenue for stroke risk assessments in patients with AF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationBiomarkersStrokeNeurofilament ProteinsHumansMaleFemaleAgedMiddle AgedRisk FactorsAged, 80 and overRisk AssessmentNatriuretic Peptide, BrainAspirin

Stichwörter der Autor:innen

atrial fibrillationbiomarkersdeathrisk assessmentstroke

Substanzen

Biomarkersneurofilament protein LNeurofilament ProteinsNatriuretic Peptide, BrainAspirin

Autor:innen und Institutionen

  • Department of Medical Sciences, Cardiology (J.A., Z.H., J.O., L.W.)Uppsala University, Sweden.
  • Uppsala Clinical Research Center (J.A., J.L., Z.H., J.O., L.W.)Uppsala University, Sweden.
  • Department of Medical Sciences, Neurology (K.S., J.B.)Uppsala University, Sweden.
  • Population Health Research Institute, McMaster University, Hamilton, ON, Canada (A.P.B., J.W.E.).
  • Department of Cardiology, University Medical Center Mainz, Johannes Gutenberg-University, Germany (A.P.B.).
  • Department of Medical Sciences, Clinical Chemistry (K.K.)Uppsala University, Sweden.

ORCID-Profile: Julia Aulin, Karl Sjölin, Johan Lindbäck, John W Eikelboom, Ziad Hijazi, Kim Kultima, Jonas Oldgren, Lars Wallentin, Joachim Burman

Zitieren

APA

Aulin, J., Sjölin, K., Lindbäck, J., Benz, A. P., Eikelboom, J. W., Hijazi, Z., Kultima, K., Oldgren, J., Wallentin, L., Burman, J., & ACTIVE A and AVERROES Investigators (2024). Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation. Circulation. https://doi.org/10.1161/circulationaha.124.069440

Vancouver

Aulin J, Sjölin K, Lindbäck J, Benz AP, Eikelboom JW, Hijazi Z, et al. Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation. Circulation. 2024. doi:10.1161/circulationaha.124.069440

BibTeX
@article{Aulin2024,
  author = {Aulin, Julia and Sjölin, Karl and Lindbäck, Johan and Benz, Alexander P and Eikelboom, John W and Hijazi, Ziad and Kultima, Kim and Oldgren, Jonas and Wallentin, Lars and Burman, Joachim and ACTIVE A and AVERROES Investigators, ACTIVE A and AVERROES Investigators},
  title = {Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation},
  journal = {Circulation},
  year = {2024},
  doi = {10.1161/circulationaha.124.069440}
}
Kostenlos starten →